Ardena has appointed Ariane de Ganck as Chief Scientific Officer. de Ganck brings a strong track record within Ardena, including her leadership of the company’s Drug Product division since 2022 and her recent role as Chief Commercial Officer.
Since joining the company in 2019, she has overseen the company’s drug product operations, led the successful acquisition and integration of the Ardena Pamplona site, and supported the expansion of Ardena’s development capabilities into aseptic fill and finish services.
As Chief Scientific Officer, Ariane will lead three key areas: Science & Technology, Project Management and CMC Regulatory Affairs. Through Science & Technology, she will advance scientific exchange across Ardena and with external industry experts and thought leaders, ensuring scientific knowledge and expertise are shared effectively across disciplines and sites. She will also oversee Project Management across all Ardena sites, supporting a consistent, science-driven and high-quality customer experience. In addition, she will continue to lead Ardena’s CMC Regulatory Affairs, helping customers navigate complex development pathways with regulatory strategies that support clinical and commercial approvals globally and across any modality.
Jeremie Trochu, CEO of Ardena, said: “As Chief Scientific Officer, Ariane will help ensure Ardena’s expertise is applied consistently across complex development programs, supporting our customers as they advance therapies with the potential to improve patients’ lives.”
de Ganck’s senior management experience spans the CRO and CDMO sectors, with expertise across drug product development, CMC regulatory affairs, biomarkers and laboratory services. Prior to joining Ardena, she worked at Biogazelle, a specialist CRO in biomarker discovery and diagnostics, until its successful sale to CellCarta.
de Ganck commented: “Scientific expertise is the foundation of how Ardena supports complex drug development, from drug substance and drug product through to bioanalysis, nanomedicines, solid-state chemistry and CMC regulatory services.”
Ardena is a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and complex therapies.